Eurand to Participate in Upcoming Investor Conferences
More News related to EURX
- Eurand N.V. (EURX) Announces Availability of ZENPEP
- Eurand Launches ZENPEP(TM) (Pancrelipase) Delayed-Release Capsules
- Eurand (EURX) Announced Phase II/III Data for Pancreatic Enzyme Product ZENPEP
- Phase II/III Clinical Study Compares Safety and Efficacy of Two Doses of ZENPEP(TM) (Pancrelipase) Delayed-Release Capsules for Fat Absorption in Adult Chronic Pancreatitis Patients With Exocrine Panc
- Eurand Reports Key Achievements and Strong Revenue Growth for Third Quarter 2009
More News related to Press Releases
- Sandler O'Neill Initiates Coverage on Wilshire Bancorp (WIBC) with a Hold
- Cowen & Co Initiates Coverage on Delcath Systems (DCTH) with an Outperform
- WBB Securities Initiates Coverage on Electro-Optical Sciences (MELA) with a Sell
- JANCO Partners Initiates Coverage on Syniverse Technologies (SVR) with a Buy; Strong Competitive Position
- Citi Initiates Coverage on AGA Medical (AGAM) with a Buy
PHILADELPHIA, PA -- (MARKET WIRE) -- 10/28/09 -- Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, is scheduled to participate in the following upcoming investor conferences:
Event: Barclays Capital Healthcare Small Cap One on One Day
Date: Tuesday, November 10, 2009
Time: 7:30 a.m. to 4:00 p.m. CT (Individual Meetings)
Place: Graves 601 Hotel
601 First Avenue North
Minneapolis, Minn.
Event: 2009 Credit Suisse Healthcare Conference
Date: Wednesday, November 11, 2009
Time: 10:00 a.m. MT (Presentation by Eurand Chief Commercial Officer
John Fraher)
Place: Arizona Biltmore
2400 East Missouri Avenue
Phoenix, Ariz.
An audio webcast of the Company's presentation at the Credit Suisse Conference will be available by accessing the investor relations section of www.eurand.com and will be available via replay for 30 days following the date of the presentation.
About Eurand
Eurand is a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies. Eurand has had six products approved by the FDA since 2001 and has a pipeline of product candidates in development for itself and its collaboration partners. Its technology platforms include bioavailability enhancement of poorly soluble drugs, custom release profiles, taste-masking orally disintegrating tablet (ODT) formulations, and drug conjugation. Eurand is a global company with facilities in the U.S. and Europe. For more information, visit www.eurand.com.
Contacts: Bill Newbould Vice President, Investor Relations Eurand N.V. +1-267-759-9335 Email Contact Nick Laudico/Sara Pellegrino The Ruth Group +1-646-536-7030/7002 Email Contact Email Contact
Related Categories
Press ReleasesStocks Mentioned
-0.35Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
